A Phase 1, Single-Center, Open-label, Single Ascending Dose and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of mRNA-0184 Administered Subcutaneously in Healthy Participants
Latest Information Update: 13 Mar 2025
At a glance
- Drugs MRNA-0184
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Moderna Therapeutics
Most Recent Events
- 28 Nov 2024 Status changed from not yet recruiting to recruiting.
- 28 Oct 2024 New trial record